Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the effects of transcutaneous electrical nerve stimulation (TENS) on bladder management, pelvic floor muscle strength, and quality of life (QoL) in patients undergoing nerve-sparing radical hysterectomy (NSRH) for cervical cancer. A total of 78 NSRH patients during May 2023-May 2024 were divided into conventional catheter management (control group, n = 39) and conventional management + TENS (intervention group, n = 39). Outcomes including urinary retention incidence, postvoid residual urine volume (PVR), catheter indwelling duration, intervention compliance, pelvic floor muscle strength grading, voiding function parameters [first desire to void (FD), bladder compliance (BC), maximum cystometric capacity (MCC)], QoL scores (EORTC QLQ-C30: functional, symptom, and global health domains), and safety were assessed. The intervention group demonstrated significantly lower urinary retention incidence, reduced PVR, and shorter catheter duration versus controls (all P < 0.05). Both groups maintained > 90% intervention compliance (P > 0.05). Post-intervention voiding parameters (FD, BC, MCC) improved more significantly in the intervention group (all P < 0.05), with superior pelvic floor muscle strength grading (P < 0.001). QoL assessment revealed lower functional domain scores and higher symptom/global health scores in the intervention group (all P < 0.001). Safety analysis showed only mild dermal reactions in the intervention group, without significant between-group difference in complication rates (P > 0.05). TENS significantly improves bladder function, pelvic floor muscle strength, and QoL in post-NSRH patients with a favorable safety profile, demonstrating substantial clinical value.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Bladder Management | No Intervention | Control group receiving conventional postoperative bladder care without TENS | |
| TENS with Standard Management | Experimental | Experimental group receiving standard care plus TENS therapy -Real-time electrode adjustment based on feedback Administered using MMK520i device (Degas Intelliance) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcutaneous Electrical Nerve Stimulation (TENS) | Device | Low-frequency electrical stimulation (800Hz) applied at CV2/S3 regions twice daily for 7 days using MMK520i device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of urinary retention after catheter removal | Proportion of patients with postvoid residual urine volume (PVR) >100 mL following initial catheter removal, assessed via bladder ultrasound. | Within 7 days post-catheter removal (typically postoperative days 14-21). |
| Measure | Description | Time Frame |
|---|---|---|
| Postvoid residual urine volume (PVR) | Quantification of residual urine volume (mL) via bladder ultrasound after voiding. | Measured immediately after catheter removal and at 1-month follow-up. |
| Catheter indwelling duration |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and adverse events | Incidence of complications (UTI, urolithiasis, pain) and TENS-related reactions (erythema, paresthesia). | Throughout the intervention period (7 days) and 1-month follow-up. |
| Intervention compliance |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | 200032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Total days from surgery to permanent catheter removal.
| Up to 30 days postoperatively. |
| Pelvic floor muscle strength grading | Assessed via vaginal examination using a 6-point scale (Grades 0-V). | At 1-month post-intervention. |
| Voiding function parameters (FD, BC, MCC) |
| Pre-intervention and 1-month post-intervention. |
| Quality of Life (EORTC QLQ-C30 scores) | Standardized scores for functional, symptom, and global health domains. | Pre-intervention and 1-month post-intervention. |
Proportion of participants completing the full TENS protocol (≥90% sessions).
| During the 7-day intervention period. |
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| D016055 | Urinary Retention |
| D059411 | Lower Urinary Tract Symptoms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004561 | Transcutaneous Electric Nerve Stimulation |
| ID | Term |
|---|---|
| D004599 | Electric Stimulation Therapy |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D012046 | Rehabilitation |
| D000698 | Analgesia |
| D000760 | Anesthesia and Analgesia |
Not provided
Not provided